Trial Profile
Phase I/II, open labeled, prospective trial to study safety and efficacy of Chidamide Plus DCAG for Relapsed/Refractory Acute myeloid leukaemia (AML).
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jun 2019
Price :
$35
*
At a glance
- Drugs Aclarubicin (Primary) ; Cytarabine (Primary) ; Decitabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Tucidinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Status changed to active, no longer recruiting as per results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 12 Feb 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.